Generics

Billions of Dollars Could be Saved through Upgrading State Drug Benefits

A new report sponsored by the Pharmaceutical Care Management Association sees potential savings of up to $5 billion in California's Medicaid program in "upgrading management of drug benefits." Prepared by The Menges Group, the report finds that such savings could be realized while maintaining benefit access and quality should "California and other state Medicaid programs .

BD Launches Simplist Generic Prefilled Injectable Products

The pharmaceutical packaging and product firm has introduced a line of prefilled injectibles designed to help improve patient safety and convenience.

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD Simplist™ ready-to-administer, line of prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD.  The first BD Simplist product BD Rx will launch is Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine. 

Your rating: None Average: 5 (1 vote)

Supreme Court Case Pits Generic Drug Makers Against Stores, Insurers

A case scheduled for argument March 25 pits pharmaceutical companies offering both generic and branded drugs against the government, stores and insurance firms.

Generic drugs have dramatically changed the pharmaceutical and health-care landscape in the last 25 years and now account for about 80 percent of prescriptions in the United States, with lower prices for consumers and insurers.

But a U.S. Supreme Court case scheduled for argument March 25 pits drug companies, generic and branded, against government officials who argue that prices for consumers would be even lower if those companies did not strike deals to restrain trade. Drugstore chains and health insurers back the government's side.

No votes yet

Mylan Launches Generic Maxalt MLT Tablets

The pharmaceutical firm has received FDA approval for its migraine treatment.

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base). These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt® Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.

Your rating: None Average: 4.5 (2 votes)

Mylan Launches Generic Version of Atacand HCT

The company has attained 180 days of marketing exclusivity on the 32/25 mg strength of the hypertension treatment.

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 16/12.5 mg, 32/12.5 mg and 32/25 mg. This product is the generic version of AstraZeneca's Atacand HCT, and is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.

No votes yet

Teva Launches Generic Glucose Control Tablets in U.S.

The company is introducing a generic version of Actos tablets, used to control blood sugar in patients with Type 2 diabetes.

Teva Pharmaceutical Industries announced the launch of an authorized generic of Actos (pioglitazone-hydrochloride tablets) 15, 30 and 45mg. Actos is marketed by Takeda Pharmaceuticals U.S.A., Inc., and used with diet and exercise for blood sugar control in adults with type 2 diabetes.

The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30.

No votes yet

Wockhardt to Launch Generic Version of BPH Drug Uroxatral

The drug, with the generic name of alfuzosin, is used to treat enlarged prostate.

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of Benign Prostatic Hyperplasia or enlarged prostate. Alfuzosin is the generic name for the brand Uroxatral marketed in the United States by Sanofi-Aventis. Wockhardt is launching the product immediately.

Your rating: None Average: 5 (2 votes)

Watson's Generic Version of Pulmicort RESPULES Receives FDA Approval

The company has received the go-ahead for the treatment, intended to treat asthma symptoms in children.

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Budesonide Inhalation Suspension 0.25mg/2mL and 0.5mg/2mL Unit-dose ampules, the generic equivalent to AstraZeneca's Pulmicort RESPULES. Watson is currently involved in patent litigation with AstraZeneca concerning this product.

No votes yet

FDA Approves Watson’s Generic Version of Plan B One-Step

Watson Pharmaceuticals has received the go-ahead to launch its generic version of the emergency contraceptive.

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice™ ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.

No votes yet

Bayshore Pharmaceuticals Announces Generic Drug Product Purchase

The company has inked an ANDA with a large generic pharmaceutical firm on a drug with an estimated $12 million in sales.

Bayshore Pharmaceuticals announces that it has acquired a pending Abbreviated New Drug Application (“ANDA”) via an Asset Purchase Agreement with a large US-based generic pharmaceutical company. Based on industry sales data, the product, which is expected to gain full FDA approval within the next quarter, has reported U.S. sales of approximately $12 million over the previous 12 month period.

No votes yet
Syndicate content